Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    2,820 result(s) found. Displaying page 67 of 141.
    «« First « Previous 63  64  65  66  67  68  69  70  71  Next» Last»»
    EudraCT Number: 2019-003087-43 Sponsor Protocol Number: SAFER Start Date*: 2021-01-12
    Sponsor Name:Synektik Spółka Akcyjna
    Full Title: A Phase I/II Seamless Adaptive, Open label study to assess Safety, Tolerability, Radiation Dosimetry, Biodistribution, and diagnostic ability of a Novel 18F-labelled Tracer, SYN2, for Positron Emis...
    Medical condition: phase II: suspected coronary artery disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003516-21 Sponsor Protocol Number: MEDI4736-NHL-001 Start Date*: 2016-04-13
    Sponsor Name:Celgene International II Sàrl
    Full Title: A Phase 1/2, open label, multicenter study to assess the safety and tolerability of durvalumab (anti-PD-L1 antibody) as monotherapy and in combination therapy in subjects with lymphoma or chronic l...
    Medical condition: Relapsed/refractory (R/R) lymphoma or R/R chronic lymphocytic leukemia (CLL) previously treated with at least one systemic therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10029592 Non-Hodgkin's lymphomas NEC HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-005229-95 Sponsor Protocol Number: PBKR03-001 Start Date*: 2021-08-23
    Sponsor Name:Passage Bio, Inc.
    Full Title: A Phase 1/2 Open-Label, Multicenter, Dose Ranging and Confirmatory Study to Assess the Safety, Tolerability and Efficacy of PBKR03 Administered to Pediatric Subjects with Early Infantile Krabbe Dis...
    Medical condition: Krabbe disease (globoid cell leukodystrophy) is an autosomal recessive lysosomal storage disease (LSD) caused by mutations in the gene encoding the hydrolytic enzyme galactosylceramidase (galactoce...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10023492 Krabbe's disease PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-001509-33 Sponsor Protocol Number: B9991025 Start Date*: 2018-05-31
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 1B/2 STUDY TO EVALUATE SAFETY AND ANTI-TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH THE POLY (ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH ...
    Medical condition: Locally advanced (primary or recurrent) or metastatic solid tumors, including non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), hormone receptor-positive (HR+) / human epide...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10065147 Malignant solid tumor LLT
    20.0 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed) DK (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2021-001235-12 Sponsor Protocol Number: GULLIVER-2 Start Date*: 2021-07-20
    Sponsor Name:Galecto Biotech AB
    Full Title: GULLIVER-2 - a single (open-label) and repeat dose (randomised, placebo-controlled) trial to assess the safety, tolerability and pharmacokinetics of GB1211 (Gal-3 inhibitor) in participants with he...
    Medical condition: Healthy subjects (for study Parts 1 and 3) and patients with hepatic impairment (Child Pugh B and Child Pugh C) (cirrhosis)
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004871 10052254 Hepatic impairment LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2016-001577-33 Sponsor Protocol Number: D24-DIPG Start Date*: 2016-11-03
    Sponsor Name:Clínica Universidad de Navarra
    Full Title: Phase I Trial of DNX-2401 for Diffuse Intrinsic Pontine Glioma newly diagnosed in pediatric patients.
    Medical condition: Diffuse Intrinsic Pontine Glioma newly diagnosed in pediatric patients.
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-000911-25 Sponsor Protocol Number: BST-LT-01 Start Date*: 2019-02-12
    Sponsor Name:Banc de Sang i Teixits
    Full Title: A prospective multicenter open, not controlled phase Ib-II clinical trial to assess the safety and immunologic efficacy of virus-specific T lymphocytes from the best donor in receptors of hematopoi...
    Medical condition: CMV viral infection in an immunocompromised host
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10021819 Infection in marrow transplant recipients LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001505-22 Sponsor Protocol Number: BST-COVID-01 Start Date*: 2020-04-23
    Sponsor Name:Banc de Sang i Teixits
    Full Title: Double-blind, randomized, parallel, placebo-controlled pilot clinical trial, nested in a prospective cohort observational study, for the evaluation of the efficacy and safetyof two doses of WJ-MSC ...
    Medical condition: Acute respiratory distress syndrome
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001052 Acute respiratory distress syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-000177-80 Sponsor Protocol Number: DCC-2618-01-008 Start Date*: 2021-08-17
    Sponsor Name:Deciphera Pharmaceuticals, LLC
    Full Title: A Phase 1b/2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Ripretinib in Combination with Binimetinib in Patients with Gastrointestinal Str...
    Medical condition: Gastrointestinal Stromal Tumor (GIST)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-003108-56 Sponsor Protocol Number: PULMESCEL-1 Start Date*: 2018-02-09
    Sponsor Name:Fundación para la investigación biomédica del Hospital Ramón y Cajal
    Full Title: Clinical Trial: Feaseability and security of the treatment of Bronchopulmonary Dysplasia in preterm babies with expanded umbilical cord allogenic fetal mesenchymal stem cells.
    Medical condition: 10 preterm babies under 28 weeks of gestational age and under 1250 grams of weight, at high risk of presenting pulmonary damage.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10006475 Bronchopulmonary dysplasia PT
    Population Age: Preterm newborn infants, Newborns, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001434-34 Sponsor Protocol Number: MPN19H2 Start Date*: 2019-07-04
    Sponsor Name:Department of haematology, Zealand university hospital
    Full Title: Dual Vaccine Trial in Myeloproliferative Neoplasms
    Medical condition: Myeloproliferative Neoplasms
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10028576 Myeloproliferative disorder LLT
    20.1 100000004864 10036061 Polycythemia vera LLT
    20.1 100000004864 10015494 Essential thrombocythemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-000656-99 Sponsor Protocol Number: REMPEX-507 Start Date*: 2023-09-28
    Sponsor Name:Rempex Pharmaceuticals-Melinta Therapeutics
    Full Title: An Open label, Dose-finding, Pharmacokinetics, Safety, and Tolerability Study of a Single Dose Infusion of VABOMERE® (Meropenem-Vaborbactam) in Pediatric Subjects From Birth to Less Than 18 Years o...
    Medical condition: Suspected or confirmed negative bacterial infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    20.0 10021881 - Infections and infestations 10004047 Bacterial infections NEC HLT
    20.1 10021881 - Infections and infestations 10060945 Bacterial infection PT
    20.1 100000004862 10018657 Gram-negative bacterial infection NOS LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2021-003955-40 Sponsor Protocol Number: TMC114FD1HTX1004 Start Date*: 2022-05-10
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Single-dose, Open-label, Randomized, Crossover Pivotal Bioequivalence Study in Healthy Participants to Assess the Bioequivalence of Darunavir 600 mg in the Presence of Cobicistat 90 mg When Admin...
    Medical condition: Human Immunodeficiency Virus-1 (Healthy participants)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10020443 Human immunodeficiency virus syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005090-26 Sponsor Protocol Number: Kleb4V01 Start Date*: 2021-06-21
    Sponsor Name:LimmaTech Biologics AG
    Full Title: Safety and immunogenicity of a Klebsiella pneumoniae tetravalent bioconjugate vaccine (Kleb4V) administered to healthy adults: A FTIH phase I/II randomized and controlled study.
    Medical condition: Klebsiella pneumoniae (K. pneumoniae), a gram negative Enterobacteriaceae, is an opportunistic pathogen leading to hospital- and community-acquired infections (urinary tract infections, pneumonia a...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10046859 Vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001115-73 Sponsor Protocol Number: Regenerate-1 Start Date*: 2018-06-05
    Sponsor Name:Uppsala University Hospital
    Full Title: A Phase I/II, 2-Arm, Open Label, Single Centre Study to Investigate the Safety and Effect of Oral GABA Therapy on β-cell Regeneration in Type 1-diabetes Patients
    Medical condition: Type 1 diabetes
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001879-43 Sponsor Protocol Number: B9991005 Start Date*: 2016-03-11
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A Phase 1b/2, Open-Label, Dose-Finding Study to Evaluate Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Avelumab (MSB0010718C) in Combination with Either Crizotinib or PF-06463922 in Pa...
    Medical condition: Anaplastic Lymphoma Kinase (ALK) (negative and positive) Non-Small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10025051 Lung cancer non-small cell stage II LLT
    18.1 100000004864 10025052 Lung cancer non-small cell stage III LLT
    18.1 100000004864 10025055 Lung cancer non-small cell stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-001411-82 Sponsor Protocol Number: HIPRA-HH-1 Start Date*: 2021-08-11
    Sponsor Name:LABORATORIOS HIPRA, S.A.
    Full Title: A phase I/IIa study to evaluate safety and immunogenicity of recombinant protein RBD fusion dimer candidate vaccine against SARS-CoV-2 in adult healthy volunteers.
    Medical condition: SARS-CoV-2
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084272 SARS-CoV-2 infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000862-31 Sponsor Protocol Number: GLAS Start Date*: 2017-09-28
    Sponsor Name:Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH)
    Full Title: A phase Ib/IIa pilot trial of the oral Hedgehog Signalling Inhibitor, Glasdegib, in Patients with sclerotic chronic graft-versus-host disease refractory to second-line treatment
    Medical condition: Adult patiens with sclerotic chronic graft-versus-host disease refractory to second-line treatment.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000109195 10074474 Transplantation complications HLT
    20.0 100000022080 10067862 Allogeneic stem cell transplantation LLT
    20.0 10022117 - Injury, poisoning and procedural complications 10074555 Transplantation complication PT
    20.0 100000020501 10018653 Graft-versus-host disease LLT
    20.0 100000022080 10067859 Allogenic stem cell transplantation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005998-27 Sponsor Protocol Number: AKF-398 Start Date*: 2021-03-12
    Sponsor Name:University of Southern Denmark
    Full Title: Interleukin-6 inhibitors and drug-drug interactions in patients with Rheumatoid Arthritis.
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004859 10060732 Rheumatoid arthritis flare up LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000763-33 Sponsor Protocol Number: 20160283 Start Date*: 2017-12-01
    Sponsor Name:Amgen, Inc.
    Full Title: A Phase 1b/2 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Efavaleukin Alfa in Adult Subjects with Steroid Refractory Chronic Graft versu...
    Medical condition: Steroid Refractory Chronic Graft versus Host Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 63  64  65  66  67  68  69  70  71  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Apr 05 10:14:35 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA